Fundación MEDINA researchers use a variety of screening technologies and set-up modifications in their work to identify risks in cardiovascular safety and drug-drug interactions. Scientists at the organization, an outgrowth of the Merck Sharp and Dohme (MSD) Basic Research Center in Madrid, typically use tools, including anti-infective or biochemical inhibition assays and dose-response assay panels, for determining compound risks.
The research group has licensed the Screener lead-discovery platform from Genedata, which is based in Switzerland, for data processing, management and analysis for use in its natural product screening and lead evaluation services. Those services span single-plate measurements to large-scale screens, according to an announcement.
Screener includes the Condoseo module for dose-response curve fitting and the Kinetics Analyzer module for capturing time-series data. Version 7.0 of the platform launched last summer.
One benefit that the research organization sees in Screener is its ability to align disparate technologies and research groups via integration of third-party infrastructure and the templating of complex assay setups, the announcement says. In its formation, the research group had inherited "a large and disparate instrument park," the components of which needed to be aligned to build the organization.
- here's Genedata's announcement